3:00 PM - 6:30 PM

9:00 AM - 5:30 PM

9:00 AM - 1:30 PM

The course is a remarkable platform for learning, networking, and advancing the understanding of clinical pharmacology in the context of viral, bacterial and fungal infections. It presents a unique opportunity for interdisciplinary cross-fertilization of ideas and incorporation of new approaches in all areas of anti-infective agents, from target identification to clinical application.

Combined as in-person and virtual participation to ensure a wide-reaching and inclusive engagement, the course brings together experts from different fields. Now in its 20th edition, it has progressively expanded to encompass a broad range of topics of clinical pharmacology, thus allowing every participant to exchange the latest scientific knowledge and engage in a comprehensive educational experience.

Not only designed for clinicians who wish to deepen their knowledge about PK/PD aspects of HIV research and medicine, the 3-day course is also a focus on novel issues covering proper use of antibiotics and antifungal agents. Monoclonal antibodies prophylaxis and up-to-date treatment approaches for patients with HIV, RSV and COVID will be also explored. Additionally, pharmacological principles and clinical practical competence in the areas of long-acting anti-infective agents will be widely analyzed and discussed.

Upon completion of this course, participants will be better able to:

• Recognize the role of PK/PD analysis in the development and evaluation of anti-infective agents.
• Be aware of PK variability of anti-infective drugs and cope with its association with tissue drug penetration and clearance.
• Optimize strategies for long-term success in the treatment of HIV infection and prevent or minimize DDIs.
• Describe the new challenges of latest treatments for viral, bacterial and fungal infections and manage treatment optionsfor high-risk or special patient groups.
• Analyze the use of monoclonal antibodies therapies and explore new strategies for prevention of infectious diseases.
• Look at real clinical scenarios, reviewing findings and management in the light of PK/PD data and clinical practices guidelines.
• Provide foundational information on hepatitis delta virus (HDV), addressing gaps in HDV screening and diagnosis and discussing emerging therapeutic options. 
  

HealthData Consulting S.r.l. 

via Morghen 27, 10143 Turin, Tel. +39 011 0267950 - Fax +39 011 0267954 - Mail segreteria@hdcons.it, P.IVA 01429280058, REA 1125824